Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 20/20 | 0.69 |
| ▸ | EGFR | P00533 | 10/20 | 0.69 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608156 | 0.98 | ERBB2 (0.71) | ERBB2EGFRERBB4KCNH2 | |
| SCHEMBL5258335 | 0.90 | ERBB2 (0.56) | ERBB2EGFRERBB4 | |
| SCHEMBL3617722 | 0.90 | ERBB2 (0.56) | ERBB2EGFRERBB4 | |
| SCHEMBL4176232 | 0.89 | ERBB2 (0.68) | ERBB2EGFRERBB4KCNH2 | |
| SCHEMBL3616794 | 0.87 | ERBB2 (0.59) | ERBB2EGFRERBB4 | |
| SCHEMBL4180711 | 0.87 | ERBB2 (0.71) | ERBB2EGFRERBB4KCNH2 | |
| SCHEMBL4396224 | 0.84 | ERBB2 (0.96) | ERBB2EGFRKCNH2 | |
| SCHEMBL4393448 | 0.84 | ERBB2 (0.96) | ERBB2EGFRKCNH2 | |
| SCHEMBL5401248 | 0.84 | ERBB2 (0.81) | ERBB2EGFRKCNH2 | |
| SCHEMBL3610447 | 0.82 | ERBB2 (0.49) | ERBB2EGFRERBB4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029696-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | claimed |
| EP-1858885-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2007-11-28 | — | — | EP | claimed |
| WO-2006092574-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | claimed |
| US-20100029696-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| EP-1858885-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006092574-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2006-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029696-A1 | INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ERBB2, ABL1, MKI67 | ERBB2 1/4885EGFR 4/4885ERBB4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.